Emerging targeted therapies for breast cancerARNEDOS, Monica; SEIDMAN, Andrew D.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, vii, 321-340 [21 p.]Article

The evolving role of gemcitabine in the management of breast cancerSEIDMAN, Andrew D.Oncology. 2001, Vol 60, Num 3, pp 189-198, issn 0030-2414Article

Treatment Strategies for Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast CancerSEIDMAN, Andrew D.Seminars in oncology. 2008, Vol 35, Num 2, issn 0093-7754, 37 p., SUP2Serial Issue

Dose-dense treatment prolongs disease-free survival of women with node positive breast cancerCHAU DANG; SEIDMAN, Andrew D.Cancer treatment reviews. 2003, Vol 29, Num 5, pp 453-456, issn 0305-7372, 4 p.Article

Preclinical Investigations With Epothilones in Breast Cancer ModelsBURNS, Howard A.Seminars in oncology. 2008, Vol 35, Num 2, issn 0093-7754, S15-S21, SUP2Article

Clinical Studies With Epothilones for the Treatment of Metastatic Breast CancerVAHDAT, Linda T.Seminars in oncology. 2008, Vol 35, Num 2, issn 0093-7754, S22-S30, SUP2Article

Adjuvant endocrine treatment of early breast cancerLONNING, Per Eystein.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, v, 223-238 [17 p.]Article

Hormonal therapy for advanced breast cancerRUGO, Hope S.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, vi, 273-291 [20 p.]Article

Monotherapy options in the management of metastatic breast cancerSEIDMAN, Andrew D.Seminars in oncology. 2003, Vol 30, Num 2, pp 6-10, issn 0093-7754, 5 p., SUP3Article

Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer : Intrinsic and AcquiredCHIEN, A. Jo; MOASSER, Mark M.Seminars in oncology. 2008, Vol 35, Num 2, issn 0093-7754, S1-S14, SUP2Article

Emerging Agents in the Treatment of Anthracycline-and Taxane-Refractory Metastatic Breast CancerDEAN-COLOMB, Windy; ESTEVA, Francisco J.Seminars in oncology. 2008, Vol 35, Num 2, issn 0093-7754, S31-S38, SUP2Article

Brain metastases : Old problem, new strategiesNGUYEN, Teri D; ABREY, Lauren E.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, vii-viii, 369-388 [22 p.]Article

Adjuvant chemotherapy for early-stage breast cancerMCARTHUR, Heather L; HUDIS, Clifford A.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, v, 207-222 [17 p.]Article

HER2-positive advanced breast cancerROBERT, Nicholas J; FAVRET, Anne M.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, vi-vii, 293-302 [12 p.]Article

Trastuzumab (herceptin) for early-stage breast cancerISMAEL, Gustavo; DORNELLES ROSA, Daniela; DE AZAMBUJA, Evandro et al.Hematology/oncology clinics of North America. 2007, Vol 21, Num 2, issn 0889-8588, v-vi, 239-256 [20 p.]Article

Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyVOGELZANG, Nicholas J; BENOWITZ, Steven I; PATEL, Jyoti D et al.Journal of clinical oncology. 2012, Vol 30, Num 1, pp 88-109, issn 0732-183X, 22 p.Article

Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast CancerTRAINA, Tiffany A; RUGO, Hope S; SEIDMAN, Andrew D et al.Journal of clinical oncology. 2010, Vol 28, Num 4, pp 628-633, issn 0732-183X, 6 p.Article

Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerDANG, Chau T; D'ANDREA, Gabriella M; HURRIA, Arti et al.Clinical cancer research. 2004, Vol 10, Num 17, pp 5754-5761, issn 1078-0432, 8 p.Article

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors : Final Results of Cancer and Leukemia Group B Protocol 9840SEIDMAN, Andrew D; BERRY, Donald; UNGARO, Peter et al.Journal of clinical oncology. 2008, Vol 26, Num 10, pp 1642-1649, issn 0732-183X, 8 p.Article

Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyKRIS, Mark G; BENOWITZ, Steven I; OBEL, Jennifer C et al.Journal of clinical oncology. 2010, Vol 28, Num 36, pp 5327-5347, issn 0732-183X, 21 p.Article

Increased dose density is feasible : A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10-or 11-day intervals with filgrastim support in women with breast cancerFORNIER, Monica N; SEIDMAN, Andrew D; HUDIS, Clifford et al.Clinical cancer research. 2007, Vol 13, Num 1, pp 223-227, issn 1078-0432, 5 p.Article

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerMODI, Shanu; SEIDMAN, Andrew D; HUDIS, Clifford A et al.Breast cancer research and treatment. 2005, Vol 90, Num 2, pp 157-163, issn 0167-6806, 7 p.Article

Phase II study of Celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsDANG, Chau T; DANNENBERG, Andrew J; HUDIS, Clifford A et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4062-4067, issn 1078-0432, 6 p., 1Article

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trialVAN POZNAK, Catherine; SEIDMAN, Andrew D; BLOCH, Renny et al.Breast cancer research and treatment. 2001, Vol 66, Num 3, pp 239-248, issn 0167-6806Article

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationSEIDMAN, Andrew D; FORNIER, Monica N; GILEWSKI, Teresa et al.Journal of clinical oncology. 2001, Vol 19, Num 10, pp 2587-2595, issn 0732-183XArticle